SK3 Group, Inc.
SK3 Group, Inc.
Your view on SKTO
Overview
What the company does, where it operates, and who runs it.
About SK3 Group, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Artemus Mayor
- Headquarters
- 448 South Hill Street, Los Angeles, CA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Artemus Mayor
- Headquarters
- 448 South Hill Street, Los Angeles, CA, US
SK3 Group, Inc. provides management advisory, licensing, and marketing services for medical marijuana collectives in California.
It licenses various products for marketing and sale, including the YAK line of medical marijuana edibles; Canna-Loz, a delivery system for large doses of phyto-cannabinoids; Yeti, a pre-roll for pain relief; and Dharmanol, a proprietary technology that extracts, stabilizes, and preserves the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form.
The company was formerly known as CTT International Distributors, Inc. and changed its name to SK3 Group, Inc. in May 2007. The company was founded in 2000 and is headquartered in Los Angeles, California. SK3 Group, Inc. is a subsidiary of Healthcare of Today, Inc.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for SK3 Group, Inc., and the rating behind it. SKTO last traded at $0.0000, 0.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SK3 Group, Inc.. Starting points for SK3 Group, Inc.: P/E 0.0, EPS $2.43, beta -5.45 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SK3 Group, Inc.. SK3 Group, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SK3 Group, Inc.. Trailing twelve-month EPS for SK3 Group, Inc. stands at $2.43. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SK3 Group, Inc.. SK3 Group, Inc. has reported as a listed company since 2008. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SK3 Group, Inc. valued side by side against its closest peers. SK3 Group, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold SK3 Group, Inc., and how their positions are changing. At a $1,395 market value, institutional positions materially move SK3 Group, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by SK3 Group, Inc. executives and directors. Shares of SK3 Group, Inc. have traded between $0.0000 and $0.0000 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming SK3 Group, Inc.. SK3 Group, Inc. is a $1,395 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming SK3 Group, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SK3 Group, Inc.. Coverage tracks SK3 Group, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.